While free dox and SynB1-ELP-DOXO tumors were reduced by similar amounts, there is a threefold enhancement in tumor reduction between SynB1-ELP1-DOXO and non-thermally responsive control SynB1-ELP2-DOXO, indicating that our designed ELP drug carrier can be efficiently targeted to the tumor site and effectively inhibit tumor growth in the presence of externally applied, mild hyperthermia. Here, ELP1 is linked to neoplasm.